share_log

BioAffinity Technologies (NASDAQ:BIAF) Trading Down 2.8%

BioAffinity Technologies (NASDAQ:BIAF) Trading Down 2.8%

生物親和技術 (納斯達克:BIAF) 交易下跌 2.8%
Defense World ·  2023/03/15 13:51

Shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF – Get Rating) fell 2.8% during mid-day trading on Tuesday . The company traded as low as $1.52 and last traded at $1.65. 11,254 shares were traded during mid-day trading, a decline of 99% from the average session volume of 1,646,997 shares. The stock had previously closed at $1.70.

生物親和科技股份有限公司 (NASDAQ: BIAF — 獲得評級) 在星期二的中午交易期間下降了 2.8%.該公司的交易價格低至 1.52 美元，最後交易價為 1.65 美元。中間交易期間有 11,254 股，較 1,646,997 股的平均交易量下跌 99%。該股票之前已收盤 1.70 美元。

bioAffinity Technologies Stock Down 2.8 %

生物親和科技股價下跌 2.8%

The firm has a 50 day simple moving average of $1.98.

該公司擁有 50 天的簡單移動平均線 1.98 美元。

Get
取得
bioAffinity Technologies
生物親和技術
alerts:
警報：

Institutional Trading of bioAffinity Technologies

生物親和技術的機構交易

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Citadel Advisors LLC bought a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF – Get Rating) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 20,583 shares of the company's stock, valued at approximately $60,000. Citadel Advisors LLC owned approximately 0.75% of bioAffinity Technologies at the end of the most recent quarter. Institutional investors and hedge funds own 2.43% of the company's stock.

對沖基金最近購買了生物親和科技股票的新股份。城堡顧問有限責任公司買了生物親和技術公司的新股份, 公司. (NASDAQ: BIAF — 獲得評級) 在第三季度, 根據其最近的 13F 申請與美國證券交易委員會.機構投資者購買了該公司股票 20,583 股，價值約 60,000 美元。城堡顧問有限責任公司擁有約 0.75% 生物親和技術在最近一個季度結束.機構投資者和對沖基金擁有公司股票的 2.43%。

bioAffinity Technologies Company Profile

生物親和科技公司簡介

(Get Rating)

(取得評分)

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level.

BioAffinity 科技有限公司是一家生物技術公司，致力於開發非侵入性診斷測試和靶向癌症治療。該公司提供 CypAth 肺部診斷 test，用於及早發現肺癌。它還研究標靶療法以治療細胞水平的癌症。

Featured Articles

特色文章

  • Get a free copy of the StockNews.com research report on bioAffinity Technologies (BIAF)
  • Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
  • GitLab Crashes On Guidance; Analysts Defend
  • Healthcare Stocks With at Least 30 Years of Dividend Increases
  • Coinbase Pops As SVB Crumbles To Dust
  • Airlines Update Guidance, Shares Head For Different Destinations
  • 獲取有關生物親和技術研究報告的免費副本
  • 單克隆抗體？狂熱的生物服務在井噴 Q3 上激增 32％
  • GitLab 在指導上崩潰; 分析師捍衛
  • 股息增加至少 30 年以上的醫療保健股
  • 當 SVB 崩潰到灰塵時，Coinbase 持久性有機污染物
  • 航空公司更新指南，股票前往不同目的地

Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

每日接收生物親和技術的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 BioAffinity 技術和相關公司的最新新聞和分析師評級的簡要每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論